October 2, 2023
Arecor Therapeutics brings more subjects Phase I trial of its insulin candidate
Arecor Therapeutics has decided to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278, in line with the update provided within its Interim Results on 14 September.